Steven Cohen’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Steven Cohen’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-250,000	Closed	-$2.63M	–	961
2016 Q1	$2.63M	Buy	250,000 +144,999	+138%	+$2.88M	0.02%	532
2015 Q4	$3.1M	Hold	105,001	–	–	0.03%	490
2015 Q3	$3.32M	Buy	105,001 +52,501	+100%	+$2.51M	0.03%	488
2015 Q2	$3.11M	Buy	+52,500	New	+$3.7M	0.02%	526

Other funds holding PTX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Steven Cohen's PTX Position: Q2 2016 in Review

Steven Cohen sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 250,000 shares — an estimated $2.63M sold.

Steven Cohen first reported a position in PTX in Q2 2015 and held it in 4 quarters. The position peaked at $3.32M in Q3 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

Steven Cohen reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
Steven Cohen sold 250,000 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $2.63M.
Steven Cohen first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2015 and held it in 4 quarters.
Steven Cohen's Pernix Therapeutics Holdings, Inc. position peaked at $3.32M in Q3 2015.
56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on Point72 Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.